Table 1.
Clinical and demographic data for patients with rheumatoid arthritis (RA)
| Active RA (n = 22) | Remission RA (n = 20) | P value | |
|---|---|---|---|
| Female, n (%) | 16 (72.7) | 15 (75) | 0.867 |
| Age, years, mean (SD) | 58.8 (9.6) | 53.7 (10.8) | 0.346 |
| Disease duration, years, mean (SD) | 12.5 (9.8) | 8.5 (8.2) | 0.001 |
| Rheumatoid factor+, n (%) | 14 (63.6) | 11 (55) | 0.569 |
| ACPA+, n (%) | 15 (68.1) | 18 (90) | 0.085 |
| DAS28-ESR, mean (SD) | 5.41 (1.30) | 1.92 (0.32) | 0.001 |
| Biological therapy, n (%) | 14 (63.6) | 10 (50) | 0.231 |
| Prednisone, n (%) | 18 (81.8) | 2 (10) | 0.0001 |
| DMARDs, n (%) | 20 (90.9) | 16 (80) | 0.881 |
| Biopsy location | |||
| MCP, n (%) | 0 (0) | 3(15) | |
| Wrist, n (%) | 4 (18.1) | 13 (65) | |
| Knee, n (%) | 18 (81.8) | 4 (20) | |
| PD, n (%) | 22 (100) | 20 (100) | |
| PD ≥2, n (%) | 22(100) | 3 (15) | |
| SH ≥2, n (%) | 22 (100) | 16 (80) | |
| SH ≥2 + PD, n (%) | 22 (100) | 16 (80) |
SD standard deviation, ACPA anti-cyclic citrullinated peptide/protein antibody, DAS28 28-joint Disease Activity Score, ESR erythrocyte sedimentation rate, DMARD disease-modifying antirheumatic drug, MCP metacarpophalangeal joint, PD power Doppler, SH synovial hypertrophy